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*is clinical investigation compared the clinical performance of two marketed ophthalmic viscoelastic devices (OVDs): the
bacterially derived Healon PRO OVD (test) and the animal-derived Healon OVD (control) under normal use conditions during
cataract removal and lens implantation. *is prospective, multicenter, randomized, parallel, participant/evaluator masked,
postmarket investigation enrolled 139 subjects (170 eyes), 116 (143 eyes) of which were treated (73 test; 70 control group). Both
test and control OVDs were used, at a minimum, to inflate the anterior chamber and protect the endothelium prior to cataract
extraction according to the standard procedure. *e surgeon completed a postsurgery OVD clinical performance questionnaire,
and intraocular pressure (IOP) was measured before surgery and at the 1 day postoperative visit with Goldmann applanation
tonometry. Any IOP measurement of 30mmHg or higher was considered a “spike” and recorded as a study-specific, serious
adverse event. *e bacterially derived Healon PRO OVD was found to be statistically noninferior to the overall clinical per-
formance of the animal-derived Healon OVD control; thus, the primary hypothesis was satisfied. *ere were no statistically
significant differences betweenOVD groups for any of the additional endpoints relating to IOP changes or to safety, thus satisfying
additional hypotheses. *e Healon PRO OVD showed statistically significant improvements in surgeon ratings for ease of
injectability, transparency/visibility, and ease of IOL placement. *e safety profile was also similar between OVD groups with
regards to serious and/or device-related adverse events, as well as medical and lens findings. *e results of this clinical in-
vestigation support the safety and effectiveness of the bacterially derived, currently marketed Healon PRO OVD and indicate that
the intraocular surgical performance was similar between the two OVDs.
1. Introduction
Viscoelastics are indicated for use as a surgical aid in
anterior segment procedures, including cataract surgery
with or without an intraocular lens (IOL), secondary IOL
implantation, corneal transplant surgery, and glaucoma
filtration surgery [1–4]. Some established benefits of using
viscoelastic materials in cataract surgery are endothelial cell
protection and maintenance of the intraocular space [1].
*e protection provided by viscoelastics results in reduced
trauma to the cornea from inadvertent touch due to op-
erative debris from phacoemulsification or surgical in-
struments during surgery. Minimizing corneal trauma
reduces the incidence of endothelial cell loss [5–11] and
potential corneal oedema. Viscoelastics also impact the
ease of injectability and placement of the IOL as intraocular
visibility during surgery is affected by the quantity of
bubbles within the OVD. *e ease of viscoelastic removal
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affects both surgical tissue manipulation [12–14] and
postoperative IOP [15–21].
Traditional viscoelastics, such as the Healon ophthalmic
viscoelastic device (OVD), are developed from sodium
hyaluronate derived from rooster combs. Due to concerns of
crossover contamination, animal-derived products have
been losing favor in many parts of the world.*e ophthalmic
OVD under investigation (Healon PRO OVD) is a bacte-
rially derived sodium hyaluronate version, formulated to
have similar physical properties as the animal-derived
version (Healon OVD). *is clinical study compared the
clinical performance of the two OVDs under normal use
conditions during the cataract surgical procedure.
2. Materials and Methods
2.1. Trial Design. *is 2 day, prospective, multicenter,
randomized, parallel, double-masked comparative study was
an evaluation of user acceptance rates of the bacterially
derived Healon PRO OVD (test) versus the animal-derived
Healon OVD (control). Both are considered high-molecu-
lar-weight cohesive viscoelastics and are manufactured by
Johnson & Johnson Vision, Inc.
*e study was conducted at two EU sites (Germany and
Spain), and 16 surgeons participated in the study and in-
cluded 170 eyes, each randomized independently to one of
the two OVD groups in a 1 :1 ratio. Participants were
implanted with any intraocular lens type and could include
one or both eyes in the study.
2.2. Subjects. Potential participants had to satisfy the fol-
lowing criteria in, at least, one eye to be enrolled in the study:
cataract requiring extraction and posterior IOL implantation
and otherwise clear intraocular media. *ey need to be
willing to comply with examination procedures and to sign
the IEC-approved informed consent. Exclusion criteria in-
cluded pupil abnormalities, unresolved ocular surgery, or
trauma affecting visual outcomes or increasing ocular risk.
Known steroid response, ocular hypertension of ≥20mmHg,
medically controlled ocular hypertension, or glaucomatous
changes in the optic nerve were also exclusion criteria, as
were pregnancy, lactation, or hormone fluctuation with
potential refractive changes. Exclusion criteria also included
concurrent participation in any other clinical trial (or within
45 days prior to the preoperative visit).
2.3. Procedures. Sequential randomization according to the
study randomization log took place after the participant had
signed the informed consent document andmet all inclusion
and exclusion criteria. *e investigator documented which
eye would be the first to undergo surgery, if applicable, and
all study personnel concerned with data collection were
masked to the randomization log.
During surgery, masking was maintained by removing
the packaging from the randomly assigned OVD out of view
of the surgeon prior to use for inflating the anterior chamber
and coating the endothelium.
Lens removal was performed using phacoemulsification/
aspiration with or without laser fragmentation, and the
surgeon’s routine choice of commercially available IOL was
implanted prior to complete removal of the OVD. Stan-
dardization of the surgical technique across study sites was
ensured by using routine, small-incision cataract extraction
with optic/haptics placed in the capsular bag and sutureless
incision closure. Laser-assisted cataract surgery and AK or
LRI were allowed bilaterally, any surgical complications
were documented, and implantation of an IOL was at the
investigator’s discretion.
A validated ethics committee-approved questionnaire
was completed by the surgeon at the end of each surgical case
to collect investigator acceptance for the study OVD used,
and the question “Rate the overall performance of the OVD”
was used to support the primary objective of the study.
Additionally, this questionnaire collected information re-
garding the ease of injectability, quantity of bubbles,
transparency/visibility, tissue manipulation, ease of IOL
placement, and ease of removal. Each question was rated on
a 5-point scale (1� unacceptable, 3� acceptable, and
5� excellent). Consistency was ensured by using the same
study evaluator for all pre- and postoperative study-related
subject testing.
Medications were administered as consistent with the
investigators routine medication regimen.
*e operative visit supplied the primary endpoint: rate of
user acceptance as reported via surgeon questionnaire
response.
Other endpoints gathered included the following:
(1) *e rate of IOP spikes, defined as 30mmHg or
greater at 1 day postoperatively as measured by
Goldmann applanation tonometry
(2) Mean change in IOP at 1-day postoperative visit
from baseline
(3) Frequency and proportion of each slit-lamp finding
(4) All serious or device-related adverse events
2.4. Statistical Analysis. *e required sample size was cal-
culated based on the percentage of eyes with acceptable
overall performance of the OVD (defined as having a score
of 3, 4, or 5; 3� acceptable and 5� excellent). *e acceptable
overall performance rate was assumed to be 85% for both
test and control OVDs. With 71 eyes per group, the study
had 80% power to evaluate the surgeon’s acceptance rate of
test eyes as being no more than 15% worse than the surgeon
acceptance rate of control eyes, using one side of a two-sided
90% confidence interval. Adding 20% for subjects lost to
follow-up and screen failure yielded a sample size of 85 eyes
per group (170 eyes for the study).
Descriptive statistics included sample size (N), mean,
standard deviation (SD), median, minimum (Min.), and
maximum (Max.) as appropriate for continuous variables,
and frequency and proportion were computed for cate-
gorical data.
For continuous variables, statistical tests assuming
normality were generally used. Two-sample T-tests were
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used for continuous data, and the Wilcoxon rank sum test
was used for ordinal data. *e primary endpoint uses a
noninferiority method and was evaluated using a one-sided
alpha of 0.05 (with a two-sided 90% confidence interval of
the difference), and the rest of the endpoints used an alpha of
0.05 for two-sided statistical testing. All available data (Safety
Population, SP) were used for the data analysis.
*e primary endpoint was the rate of user acceptance
defined as having a response of “3, 4, or 5” in overall clinical
performance by the surgeon to the study viscoelastic
questionnaire. *e rate was reported by OVD groups, and
the differences (test minus control) were analysed using a
noninferiority margin of 15%. *e lower confidence interval
of the two-sided 90% confidence interval (equivalent to the
1-sided 95% CI) was used for evaluation, and the null hy-
pothesis was that the test OVD was 15% worse than or equal
to the control OVD. *e alternative hypothesis was that the
test OVD was not 15% worse than or equal to the control
OVD.
Other endpoints were analysed and reported by the
OVD group, including the frequency and proportion of
(1) responses to each of the other investigator ques-
tionnaire questions
(2) eyes having a postoperative IOP spike
(3) minimum and maximum change of IOP from
baseline (1-day postop IOP minus preop IOP; the
preop visit was within 45 days of surgery)
(4) Slit-lamp findings
3. Results
3.1. Participant Demographics. A total of 139 subjects (170
eyes) were enrolled, 116 (143 eyes) of which were treated, 73
eyes received the bacterially derived Healon PRO OVD (test
group) and 70 eyes received animal-derived Healon OVD
(control group). Of the remaining 27, 15 were screen failures
and 12 were discontinued. *e 12 discontinued subjects
were discontinued for the following reasons: the subject was
uncooperative/refused further participation (N� 7), the
surgeon did not use the study OVD (N� 4), and another
surgeon not in the study performed the surgery (N� 1). *e
mean patient age was 72.1 years (range: 54–94 years), 56%
were female, and all participants were Caucasian.*ere were
no statistically significant differences in the demographics
between the Healon PRO and Healon OVD groups.
Participant baseline ocular clinical characteristics/
medical findings were evaluated by slit-lamp biomicroscopy;
the findings and percentages in the two groups were similar.
Findings included blepharitis/meibomianitis, controlled
diabetes without retinopathy, dry eye, lids/adnexa (derma-
tochalasis, trichiasis, and ptosis), vitreous detachment and/
or floaters, corneal findings, and retina findings.
3.2. Questionnaire Results. *e primary endpoint related to
“the overall performance of the OVD” was obtained from
the investigator questionnaire using a 5-point scale
(1� unacceptable, 3� acceptable, and 5� excellent). *e
rates of user acceptance (“acceptable-excellent”) were 93.2%
for the Healon PRO OVD and 95.7% for the Healon OVD
(Figures 1 and 2).
*e null hypothesis was that the user acceptance rate of
the Healon PRO OVD would be 15% worse than or equal to
that of the Healon OVD. *e success criterion is defined as
having the lower 2-sided 90% confidence interval of the
difference in ratings between OVDs be greater than −15%.
*e difference in user acceptance rates between the two
groups was −2.59% (90%CI, −8.85% to 3.72%).*e lower CI
of the difference was −8.85%, which was higher than the
noninferiority margin of −15%; thus, the null hypothesis was
rejected, and it was concluded that the Healon PROV OVD
was not statistically noninferior in the overall clinical per-
formance compared to the Healon OVD.
*e investigator questionnaire also provided data on the
following variables: Ease of injectability was given high
ratings by the surgeons for both OVDs, with a majority of
the responses rated as “excellent”: 89.0% for the Healon PRO
OVD and 72.9% for the Healon OVD (Figure 3).*ere was a
statistically significant difference between OVD groups,
favouring the Healon PRO OVD (p � 0.0134) *e p values
for the questionnaire endpoints are from the two-sided
Wilcoxon rank sum test.
Quantity of bubbles was rated as “excellent” in most
instances for both OVDs: 84.9% for the Healon PRO OVD
and 77.1% for the Healon OVD control (Figure 4). Because
bubbles obscure the surgeon’s view, having a smaller
quantity of bubbles was preferred. *ere was no statistically
significant difference in the quantity of bubbles (p � 0.224)
between the two OVDs.
Transparency/visibility was rated as “excellent” in a
majority of cases for both OVDs: 91.8% for the Healon PRO
OVD and 80.0% for the control (Figure 5). *ere was a
statistically significant preference in transparency/visibility
for the Healon PRO OVD when compared to the Healon
OVD (p � 0.049).
Tissue manipulation ratings were high for both OVDs,
with over 95% of ratings being acceptable (Figure 6).
*ere was no statistically significant difference in the
scores between the two groups for tissue manipulation
(p � 0.119).
Ease of IOL placement was rated “excellent” in 90% of
the ratings for the Healon PRO OVD, with a statistically
significant improvement in ease of IOL placement between
the OVD groups favouring the Healon PRO OVD
(p � 0.029) (Figure 7).
Ease of removal was rated acceptable in all cases for both
OVDs, with a majority being rated “excellent” (Figure 8).
*ere was no statistically significant difference in the ease of
removal (p � 0.574).
3.3. Other Endpoints. *e rate of IOP spike, defined as
30mmHg or greater at 1 day postoperatively, revealed no
statistically significant difference (p � 0.999) (from two-
sided Fisher’s exact test). *e IOP spike rates for the Healon
PRO OVD and Healon OVD were 5.5% and 4.3%,
respectively.
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*e mean differences in IOP from baseline to 1 day
postoperatively were 3.2mmHg (95% CI, 1.8 to 4.6) for the
Healon PROOVD and 2.0mmHg (95%CI, 0.9 to 3.2) for the
Healon OVD (Figure 9). *e mean difference between
OVDs was −1.1mmHg (95% CI, −3.0 to 0.7), with no sta-
tistically significant difference in the change of IOP between
the Healon PRO OVD and Healon OVD (p � 0.219 from
two-sided two-sample t-test).
3.4. Ancillary Analyses. Surgical complications were rare,
with only one complication (1.4%, 1/73) of zonular damage/
rupture occurring in the Healon OVD group and one
complication (1.4%, 1/70) of vitreous loss occurring in the
Healon PRO OVD group. No surgical procedures outside of
the protocol were performed.
*e most common adverse event reported was elevated
IOP, and this was similar between groups: 6.8% (5/73) in the
Healon PRO OVD group and 4.3% (3/70) for the Healon
OVD control group.
4. Discussion
Viscoelastics are indicated for use as a surgical aid in anterior
segment procedures [1–3, 4] and have an important pro-
tective role in minimising corneal trauma [5–11]. *is
clinical study compared the clinical performance of the two
OVDs under normal use conditions during the cataract
When asked “how do you rate the overall performance of the OVD?”
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Figure 1: Rate of the overall clinical performance of the Healon PROOVD (test) andHealon OVD (control), “acceptable” having a response

















Overall clinical performance of OVD
%
Figure 2: Overall clinical performance of the Healon PROOVD (test) andHealonOVD (control), “acceptable” having a response of “3, 4, or
5” in the overall clinical performance of the study viscoelastic.
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surgical procedure and addresses the trend of moving from
animal- to bacterially derived sodium hyaluronate for use in
OVDs.
*is 2 day, prospective, multicenter, randomized, par-
ticipant/evaluator-masked clinical investigation evaluated
the acceptability of the bacterially derived Healon PROOVD
when compared to the animal-derived Healon OVD control
under normal use conditions during the cataract surgical
procedure. *e primary hypothesis was that the overall
clinical performance of the test product would be evaluated
by the surgeon to be statistically noninferior to the control
group. *e results show that the Healon PRO OVD was
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When asked “how do you rate the ease of injectability of the OVD?”
Figure 3: Ease of OVD injectability during surgery for the Healon control and Healon PRO test groups, where “user acceptable” indicated a
response of “3,” “4,” or “5.”
1-unacceptable 3-acceptable 5-excellent2 4























Healon (N = 70)
Healon PRO (N = 73)
p = 0.224
When “how do you rate the quantity of bubbles of the OVD?”
Figure 4: Quantity of bubbles during surgery for the Healon control and Healon PRO test groups, where “user acceptable” indicated a
response of “3,” “4,” or “5.”
1-unacceptable 3-acceptable 5-excellent2 4






















Healon (N = 70)
Healon PRO (N = 73)
When asked “how do you rate the transparency/visibility of the OVD ?”
p = 0.049
Figure 5: Transparency/visibility during surgery for the Healon control and Healon PRO test groups, where “user acceptable” indicated a
response of “3,” “4,” or “5.”
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statistically noninferior to the Healon OVD in the ratings for
the overall clinical performance, and thus, the primary
hypothesis was achieved and the null hypothesis rejected.
Whilst the rates of user acceptance
(“acceptable”–“excellent”) were high for both the Healon
PRO OVD and for Healon OVD, with a majority of the
ratings being “excellent,” these results indicate that the
Healon PRO OVD is an appropriate alternative to the an-
imal-derived Healon OVD.
*e use of viscoelastics aids the manipulation of surgical
tissue [12–14] and contributes to the stability of postoper-
ative IOP [15–21]. *e Healon PRO OVD showed
1-unacceptable 3-acceptable 5-excellent2 4
























Healon (N = 70)
Healon PRO (N = 73)
When asked “how do you rate the tissue manipulation of the OVD ?”
p = 0.1191
Figure 6: Tissue manipulation during surgery for the Healon control and Healon PRO test groups, where “user acceptable” indicated a
response of “3,” “4,” or “5.”
1-unacceptable 3-acceptable 5-excellent2 4





















When asked “how do you rate the ease of IOL placement using the OVD ?”
p = 0.029
Healon (N = 70)
Healon PRO (N = 73)
Figure 7: Ease of IOL placement during surgery for the Healon control and Healon PRO test groups, where “user acceptable” indicated a
response of “3,” “4,” or “5.”
1.4
1-unacceptable 3-acceptable 5-excellent2 4






















When asked “how do you rate the ease of removal of the OVD ?”
p = 0.574
Healon (N = 70)
Healon PRO (N = 73)
Figure 8: Ease of removal of the OVD during surgery for the Healon control andHealon PRO test groups, where “user acceptable” indicated
a response of “3,” “4,” or “5.”
6 Journal of Ophthalmology
statistically significant superiority when compared to the
Healon OVD in surgeon ratings for ease of injectability,
transparency/visibility, and ease of IOL placement. *ese
factors may prove particularly valuable in the implantation
of complex IOLs, in nonstandard eyes, and in securing the
reliability and predictability of all anterior eye surgeries.
During surgery, bubbles obscure the surgeon’s view; hence, a
smaller quantity of bubbles is preferred. *e study revealed
no statistically significant difference in the quantity of
bubbles between OVD groups or when surgeons rated the
OVDs for ease of tissue manipulation or ease of removal. All
ratings were graded high, with either statistical superiority or
no statistical difference between the two OVDs, again
supporting Healon PRO OVD as an appropriate alternative
to the Healon OVD.
Intraocular pressure spikes at the 1 day postoperative
visit showed no statistically significant difference between
Healon PRO and Healon OVDs. *e rate of IOP spikes
were comparable with those previously reported for other
OVDs. In addition, there was no statistically significant
difference in the mean change of IOP from baseline to 1
day between the Healon PRO OVD and Healon OVD
groups. *e safety profile was similar between OVD
groups with regards to serious and/or device-related
adverse events, medical findings, and lens findings. *ere
were no statistically significant differences between OVD
groups for the occurrence of surgical complications or
additional surgical procedures.
Potential limitations of this clinical study should be
taken into consideration when interpreting these findings.
First, the focus of the study was on qualitative not quan-
titative data; the key findings from this study were obtained
from surgeon-rated responses to questionnaires. Additional
data could, perhaps, have been gathered by calculating the
time taken on the different procedures or by including re-
fractive outcomes as a measure of success. Second, results
may have varied between surgeons/surgical technicians, but
restricting the site number to two and ensuring that only
fully-protocol-trained staff were included have helped to
minimize this random error. Finally, this trial was conducted
in the EU, and all of the participants were Caucasian, thus
limiting intersubject variety.
In conclusion, this study has demonstrated that the
overall clinical performance of the Healon PRO OVD was
noninferior to that of the Healon OVD. All study endpoints
were achieved, and results were comparable between OVD
groups. Hence, the results of this clinical investigation
support the safety and effectiveness of the bacterially de-
rived, marketed Healon PRO OVD.
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